Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics Ltd., a biotech firm focusing on neurodegenerative disease treatments, will feature in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17th. The company’s CEO, David Stamler, M.D., will represent Alterity, which is currently advancing its lead drug candidate, ATH434, through Phase 2 clinical trials for Multiple System Atrophy. Interested parties can access the webcast live or via a three-month archive on Alterity’s website.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.